ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial

ProMIS Neurosciences ( (PMN) ) has shared an announcement.

On February 25, 2025, ProMIS Neurosciences announced the dosing of multiple patients in its Phase 1b PRECISE-AD clinical trial for PMN310, a drug candidate for Alzheimer’s disease. This milestone highlights the company’s commitment to addressing the urgent need for targeted AD therapies by selectively targeting toxic oligomers, a key driver of disease progression. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with interim results expected in the first half of 2026 and topline results in the second half of 2026. The trial’s design is expected to provide robust clinical data that could differentiate PMN310 from other AD treatments, potentially offering a more effective and well-tolerated option for patients.

More about ProMIS Neurosciences

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company that focuses on developing antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company utilizes a proprietary target discovery engine to predict novel targets on misfolded proteins, with its lead product candidate, PMN310, designed to selectively bind toxic Aβ oligomers associated with AD.

YTD Price Performance: -16.67%

Average Trading Volume: 59,410

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $26.16M

For an in-depth examination of PMN stock, go to TipRanks’ Stock Analysis page.